Health Care [ 9/12 ] | Pharmaceuticals [ 45/73 ]
NASDAQ | Common Stock
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.17 Increased by +27.75% | -0.09 Decreased by -92.67% |
| Feb 24, 25 | -0.05 Increased by +70.53% | -0.08 Increased by +39.86% |
| Nov 12, 24 | -0.06 Increased by +65.29% | -0.23 Increased by +74.35% |
| Aug 5, 24 | -0.28 Increased by 0.00% | -0.21 Decreased by -33.33% |
| May 13, 24 | -0.24 Increased by +31.43% | -0.25 Increased by +4.00% |
| Feb 26, 24 | -0.17 Decreased by -13.33% | -0.15 Decreased by -13.33% |
| Nov 7, 23 | -0.17 Increased by +19.05% | -0.21 Increased by +19.05% |
| Aug 7, 23 | -0.28 Decreased by -211.11% | -0.21 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 15.39 M Increased by +6.10% | -13.58 M Decreased by -16.42% | Decreased by -88.24% Decreased by -9.72% |
| Dec 31, 24 | 18.75 M Increased by +6.77% | -15.53 M Decreased by -82.43% | Decreased by -82.79% Decreased by -70.87% |
| Sep 30, 24 | 16.87 M Increased by +7.49% | -12.70 M Decreased by -41.88% | Decreased by -75.28% Decreased by -31.99% |
| Jun 30, 24 | 14.26 M Increased by +3.69% | -16.53 M Decreased by -5.65% | Decreased by -115.94% Decreased by -1.89% |
| Mar 31, 24 | 14.50 M Increased by +39.22% | -11.66 M Increased by +47.19% | Decreased by -80.42% Increased by +62.07% |
| Dec 31, 23 | 17.57 M Increased by +19.91% | -8.51 M Increased by +40.31% | Decreased by -48.45% Increased by +50.22% |
| Sep 30, 23 | 15.69 M Increased by +26.04% | -8.95 M Decreased by -100.98% | Decreased by -57.03% Decreased by -100.77% |
| Jun 30, 23 | 13.75 M Increased by +24.43% | -15.64 M Decreased by -91.00% | Decreased by -113.79% Decreased by -53.51% |